Based on recent analysis of the emerging generic pharmaceuticals market, Frost & Sullivan has recognised Saudi Arabia-headquartered Jamjoom Pharmaceuticals with the 2020 KSA Company of the Year Award for its operational excellence and expanded product portfolio and footprint.
Implementing best practices such as the corporate governance and setting up its own R&D center, recruiting qualified staff, strictly adhering to regulatory systems and ensuring scalability, the company has established itself as the pharma partner of choice in the KSA.
“Despite a particularly challenging 2019, Jamjoom Pharmaceuticals recorded 4% year-on-year growth and maintained its position as one of the top-ranked pharma companies in the KSA,” said Dr Suhasini Molkuvan, Associate Director – Transformational Health.
“Right from the start, it focused on building a worldclass manufacturing facility.
“Its building design, layout, selection, and installation of equipment; plant validation; and other technical processes met the most stringent international industry standards.
“Owing to its strategic diversification of specialty product lines and accelerating growth in export markets, Jamjoom Pharmaceuticals has been able to expand its manufacturing facilities and grow organically.